Dermavant Presents Results of Tapinarof in Two P-III Trials for the Treatment of Psoriasis at AAD2021

April 26, 2021 Auto Bot Clinical Trials, Dermavant, P-III Trial, Presents, psoriasis, results, tapinarof, Treatment, Two 0

Shots:

  • The two P-III PSOARING 1 and PSOARING 2 trials involve evaluating Tapinarof (1% dosed, qd) vs vehicle (qd) in 1,025 patients aged 18-75yrs. with plaque psoriasis
  • Results: 2EPs & PRO, @12wks., PASI90 (18.8% and 20.9%) vs (1.6% and 2.5%), ≥4-point NRS improvement (67.5% and 59.7%) vs (46.1 and 31.3%), improvement in QoL as measured by the DLQI, ≥90% reduction in one in five patients in PASI90, improvements in itch measured with PP-NRS
  • Tapinarof is a steroid-free, cosmetically elegant, TAMA topical cream for the treatment of PsO and AD. The data will be included in NDA submission, expected in mid-2021

Click here to­ read full press release/ article | Ref: Business Wire | Image: Business Wire

The post Dermavant Presents Results of Tapinarof in Two P-III Trials for the Treatment of Psoriasis at AAD2021 first appeared on PharmaShots.